Intellia Therapeutics Inc

-4.54 (-7.08%)
5:08:13 PM EDT: $60.36 +0.73 (+1.22%)
Products, Regulatory

Intellia, Regeneron Present Interim Data From Phase 1 Study Of Crispr-Based NTLA-2001

Published: 06/24/2022 12:37 GMT
Intellia Therapeutics Inc (NTLA) - Intellia and Regeneron Present Updated Interim Data From Phase 1 Study of Crispr-based Ntla-2001 for the Treatment of Transthyretin (attr) Amyloidosis Demonstrating That Deep Serum Ttr Reductions Remained Durable After a Single Dose.
Intellia Therapeutics Inc- at All Four Dose Levels, Ntla-2001 Was Generally Well Tolerated Through Follow-up Period.
Intellia Therapeutics Inc- Plan to Present First Interim Data From Cardiomyopathy Arm in Second Half of 2022.
Intellia Therapeutics- Results Demonstrated Sustained Durability of Serum Transthyretin (ttr) Reduction Through Last Measured Timepoint in Ongoing Observation.
Intellia Therapeutics Inc- Enrollment Across Both Attrv-pn and Attr-cm Patient Populations is Expected to Complete in 2022.